Login to Your Account


AstraZeneca's CEO Exits as Firm Enters Patent Cliff Free Fall

By Nuala Moran
Staff Writer

Wednesday, May 2, 2012
LONDON – AstraZeneca plc is expected to boost dealmaking and M&A activity after CEO David Brennan gave in to pressure from shareholders last week and agreed to resign his post.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription